Eloxatin

(Oxaliplatin)

ApprovedSmall molecule

Oxaliplatin is a chemotherapy drug used to treat colorectal cancer and other cancers by damaging cancer cell DNA to stop them from growing and dividing.[2] Eloxatin is currently approved and in use across 147 indications[4].[1]

Eloxatin is one of 1443 small molecule programs targeting Colorectal Cancer. It is currently in Approved.

147

Indications

1,240

Total Trials

Active Trials

1,442

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Colorectal CancerNot yet recruiting

Gastroesophageal Junction AdenocarcinomaRecruiting

Pancreatic AdenocarcinomaCompleted

Ovarian CancerWithdrawn

AdenocarcinomaActive, not recruiting

Liver CancerUnknown status

Rectal AdenocarcinomaRecruiting

Advanced Biliary Tract CarcinomaCompleted

Clinical Stage IV Gastric Cancer AJCC V8Active, not recruiting

Gastric NeoplasmsActive, not recruiting

Colorectal CancerApproved

Not yet recruiting

Gastroesophageal Junction AdenocarcinomaPhase 3

Recruiting

Pancreatic AdenocarcinomaPhase 3

Completed

Ovarian CancerPhase 2

Withdrawn

AdenocarcinomaPhase 3

Active, not recruiting

Liver CancerPhase 3

Unknown status

Rectal AdenocarcinomaPhase 2

Recruiting

Advanced Biliary Tract CarcinomaPhase 2

Completed

Clinical Stage IV Gastric Cancer AJCC V8Phase 1

Active, not recruiting

Gastric NeoplasmsPhase 3

Active, not recruiting

Showing 10 of 147 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Eloxatin

Teva

Approved

8 2

Adenocard

Astellas

Preclinical

2 3

Voltaren

Novartis

Preclinical

1 4

Duragesic-100

CCephalon

Preclinical

2 5

Tricor

JJagotec

Preclinical

1 6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Rilvegostomig

AstraZeneca

Preclinical

1 8

Tianeptine

Pfizer

Preclinical

1 9

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 10

Naltrexone/bupropion

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Locally-Advanced Rectal Cancer

NCT04304209

Phase 1/2Recruiting

Advanced or Metastatic Solid Tumors

NCT04495296

Phase 1Active, not recruiting

Pancreatic Cancer

NCT06532344

Phase 1Recruiting

Metastatic Colorectal Cancer

NCT06825624

Q2 2027

Phase 2Active, not recruiting

Pancreatic Cancer

NCT04481204

Q3 2027

Not yet recruiting

Efficacy and Safety

NCT06504901

Clinical

Trials by Indication[1]

Colorectal Cancer27 trials

Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Completed·UUniversity of Chicago·Phase 1/2·NCT00026299·14 enrolled

A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer

Unknown status· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT04337879·56 enrolled

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169777

Show 24 more trials

DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2/3·NCT02415699·100 enrolled

Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT00055822·16 enrolled

Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer

Terminated·NNSABP Foundation Inc·Phase 3·NCT00268463·22 enrolled

Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT00544349·45 enrolled

Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer.

Recruiting·NNizhny Novgorod Regional Clinical Oncology Center·Phase 2·NCT06888843·160 enrolled

Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 3·NCT02785146·230 enrolled

Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer

Completed·MMedical Research Council·Phase 2/3·NCT00975897·3,240 enrolled

Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Completed·UUNICANCER·Phase 2·NCT00006050

METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin

Active, not recruiting·UUniversity Hospital, Akershus·Phase 2·NCT05504252·80 enrolled

Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00043004·119 enrolled

Combination Chemotherapy in Treating Patients With Colorectal Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00039208

Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer

Completed·UUniversity of Pittsburgh·Phase 2·NCT00177307·40 enrolled

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05839470·20 enrolled

Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer

Completed·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT01022541·47 enrolled

Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer

Terminated·HHokkaido Gastrointestinal Cancer Study Group·Phase 2·NCT00209703·30 enrolled

Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer

Completed·NNYU Langone Health·Phase 1/2·NCT00005050

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00492999·64 enrolled

Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00438737·100 enrolled

TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00399750·373 enrolled

Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00100841·66 enrolled

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Recruiting·SSun Yat-sen University·Phase 3·NCT05236972·323 enrolled

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT04301557·25 enrolled

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00003594·1,691 enrolled

Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure

Completed·CCentre Georges Francois Leclerc·Phase 2·NCT01348412·31 enrolled

Metastatic Colorectal Cancer26 trials

A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 4·NCT01588990·128 enrolled

Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer

Completed·HHellenic Oncology Research Group·Phase 2·NCT01024504·46 enrolled

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00016978·40 enrolled

Show 23 more trials

Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Completed·UUNICANCER·Phase 2·NCT00104689·60 enrolled

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Recruiting·SShanghai Zhongshan Hospital·Phase 1·NCT06225622·78 enrolled

Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

Completed·RRoswell Park Cancer Institute·N/A·NCT00040820

Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer

Terminated·RRoswell Park Cancer Institute·Phase 1/2·NCT00087334·10 enrolled

Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00126256·570 enrolled

Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Completed·UUNICANCER·Phase 2·NCT00066274

Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003287·554 enrolled

Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

Unknown status·NNSABP Foundation Inc·Phase 1·NCT03626922·33 enrolled

Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer

Completed·MMedical Research Council·Phase 3·NCT00008060

Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

Terminated·CChiron Corporation·Phase 2·NCT00051688

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

Terminated·—·Phase 2·NCT00602329·5 enrolled

Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Completed·SSwiss Cancer Institute·Phase 1/2·NCT00217711·23 enrolled

Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer

Completed·PPrologue Research International·Phase 2·NCT00016198

Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT00123851·32 enrolled

Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer

Completed·LLudwig Institute for Cancer Research·Phase 1·NCT00199797·20 enrolled

FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00501410·86 enrolled

ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer

Recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT06825624·560 enrolled

First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer

Unknown status·IIstituto Oncologico Veneto IRCCS··NCT03451370·121 enrolled

First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

Completed·GGruppo Oncologico del Nord-Ovest·Phase 3·NCT03231722·435 enrolled

Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Unknown status· Sanofi logo

Sanofi·Phase 3·NCT00008281

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2/3·NCT00274872·600 enrolled

Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.

Completed·LLudwig-Maximilians - University of Munich·Phase 2·NCT00254137·92 enrolled

Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00006468

Pancreatic Cancer15 trials

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Active, not recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT06532344·32 enrolled

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Recruiting·EErasmus Medical Center·Phase 3·NCT04927780·378 enrolled

Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer

Unknown status·UUniversity of Ulm·Phase 2·NCT00690300·44 enrolled

Show 12 more trials

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01821612·23 enrolled

Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

Unknown status·LLudwig-Maximilians - University of Munich·Phase 2·NCT01729481·150 enrolled

Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer

Completed·TTechnical University of Munich·Phase 2·NCT00425841·29 enrolled

Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer

Unknown status·SSeattle Cancer Treatment and Wellness Center·Phase 2·NCT00323583·80 enrolled

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Completed·SSWOG Cancer Research Network·Phase 1/2·NCT01959139·126 enrolled

Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191568·45 enrolled

Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer

Completed·SSoonchunhyang University Hospital·Phase 2·NCT01505413·33 enrolled

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04481204·105 enrolled

Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer

Completed·RRoyal Marsden NHS Foundation Trust·Phase 1·NCT01048320·36 enrolled

Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT00275119

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Completed·UUniversity of Nebraska·Phase 2·NCT00089024·29 enrolled

Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00112528·53 enrolled

Gastric Cancer12 trials

Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive

Completed·FFundación para el Progreso de la Oncología en Cantabria·Phase 2·NCT01503983·45 enrolled

PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy

Completed·SShanghai Cancer Hospital, China·Phase 3·NCT03013010·204 enrolled

Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05974059·20 enrolled

Show 9 more trials

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer

Active, not recruiting·NNational Cancer Center Hospital East·Phase 2·NCT04745988·43 enrolled

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Withdrawn·OOhio State University Comprehensive Cancer Center·Phase 1·NCT05296005

Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 4·NCT05498766·702 enrolled

Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT03382600·100 enrolled

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

Completed· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 3·NCT03006705·800 enrolled

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT03745170·650 enrolled

The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer

Completed·SShanghai University of Traditional Chinese Medicine·Phase 2/3·NCT03607656·270 enrolled

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Not yet recruiting·FFujian Medical University·Phase 3·NCT05914610·100 enrolled

Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

Active, not recruiting·YYu jiren·Phase 2·NCT04515615·52 enrolled

Esophageal Cancer6 trials

Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy

Terminated·—·Phase 2·NCT02392377·1 enrolled

A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer

Completed·CCancer Trials Ireland·Phase 2·NCT01710592·35 enrolled

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06109467·36 enrolled

Show 3 more trials

Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT01928290·67 enrolled

Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00539617·7 enrolled

Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer

Completed·UUNICANCER·Phase 2/3·NCT00861094·266 enrolled

83 more indications

Locally-advanced Rectal Cancer6 trials

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT04304209·195 enrolled

Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer

Completed·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT02340949·180 enrolled

Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)

Recruiting·FFudan University·Phase 2·NCT07150949·138 enrolled

Show 3 more trials

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

Recruiting·UUniversity of Miami·Phase 1·NCT05412082·25 enrolled

Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer

Completed·CCancer Research UK·Phase 3·NCT00427713·800 enrolled

Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT00828672·84 enrolled

Liver Cancer5 trials

Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery

Unknown status·NNational Cancer Centre, Singapore·Phase 2·NCT00471484·54 enrolled

Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00483405·33 enrolled

Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2·NCT00941967·78 enrolled

Show 2 more trials

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Unknown status·ZZhujiang Hospital·Phase 3·NCT05701436·144 enrolled

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Unknown status·ZZhujiang Hospital·Phase 3·NCT05766605·90 enrolled

Radiation Therapy5 trials

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00321685·57 enrolled

Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT00383695·164 enrolled

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03300544·3 enrolled

Show 2 more trials

Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery

Completed·—·Phase 2·NCT01263171·60 enrolled

Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT01818973·45 enrolled

Non-Small Cell Lung Cancer4 trials

Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer

Terminated·UUniversity of Louisville·Phase 1·NCT00268151·24 enrolled

Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00004126·38 enrolled

A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment

Unknown status·KKorean South West Oncology Group·Phase 2·NCT01497041·35 enrolled

Show 1 more trial

AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer

Completed·NNCIC Clinical Trials Group·Phase 1·NCT00343408·31 enrolled

Patients With Advanced Solid Tumors3 trials

Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

Completed· Eisai logo

Eisai·Phase 1/2·NCT00374660·63 enrolled

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00006465·22 enrolled

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01233505·16 enrolled

Rectal Cancer3 trials

A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT02694718·60 enrolled

Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT01060007·80 enrolled

Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer

Completed·NNational Cancer Institute, Naples·Phase 2·NCT01481545·62 enrolled

Stage III Colon Cancer3 trials

GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer

Completed·UUniversity of Rochester·Phase 2·NCT00262808·50 enrolled

Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00004931·2,472 enrolled

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Unknown status·AAlliance for Clinical Trials in Oncology·Phase 3·NCT01150045·2,527 enrolled

Gemcitabine2 trials

Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

Completed·KKrankenhaus Nordwest·Phase 2/3·NCT02172976·40 enrolled

Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT00452881·151 enrolled

Oxaliplatin2 trials

Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract

Completed·LLeonard Appleman·Phase 2·NCT03159143·22 enrolled

Long Term Effect of Oxaliplatin Treatment in Cancer Survivors

Completed·UUniversity Hospital, Clermont-Ferrand··NCT02970526·409 enrolled

Biliary Tract Cancer2 trials

Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer

Withdrawn·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT04796454

EXIBIT: Oxaliplatin in Biliary Tract Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00174564·67 enrolled

Adjuvant Treatment2 trials

MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV

Completed· Sanofi logo

Sanofi·Phase 4·NCT00263055

MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT00275210·2,246 enrolled

Adenocarcinoma2 trials

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Recruiting·FFudan University·Phase 3·NCT04997837·433 enrolled

Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00525785·58 enrolled

Hepatocellular Carcinoma2 trials

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT00142467·33 enrolled

Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)

Terminated·RRigshospitalet, Denmark·Phase 2·NCT00351195·39 enrolled

Metastatic Head and Neck Cancer2 trials

Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer

Completed·UUniversity of Miami·Phase 2·NCT00448552·30 enrolled

Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer

Terminated·NNang Kuang Pharmaceutical Co., Ltd.·Phase 2·NCT01370876·46 enrolled

Rectal Adenocarcinoma2 trials

Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT00625183·5 enrolled

Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)

Completed·SSir Run Run Shaw Hospital·Phase 2·NCT05216653·32 enrolled

Esophageal Adenocarcinoma2 trials

Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma

Terminated·UUniversity of Colorado, Denver·N/A·NCT00430027·8 enrolled

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04662710·895 enrolled

Nasopharyngeal Carcinoma1 trial

Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma

Completed· Sanofi logo

Sanofi·Phase 2·NCT00436800·41 enrolled

Metastatic Cancer1 trial

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00005860

Microsatellite Instability1 trial

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Not yet recruiting·AAkeso·Phase 3·NCT07412613·386 enrolled

PD-1 Inhibitor1 trial

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Recruiting·FFudan University·Phase 2·NCT06455124·60 enrolled

Stomach Cancer1 trial

S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00335959·7 enrolled

Transplantation1 trial

Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos

Unknown status·UUniversity of Pisa··NCT03668418·120 enrolled

Primitive Neuroectodermal Tumor1 trial

Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Completed·PPediatric Brain Tumor Consortium·Phase 2·NCT00047177·43 enrolled

Chemotherapy1 trial

LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

Active, not recruiting·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2·NCT03255434·160 enrolled

Myelodysplastic Syndromes1 trial

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00480987·27 enrolled

Advanced Cancer1 trial

Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00066625·30 enrolled

Head and Neck Cancer1 trial

Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer

Terminated·UUniversity of California, Irvine·Phase 2·NCT00256308·6 enrolled

Advanced Biliary Tract Carcinoma1 trial

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03111732·11 enrolled

Unresectable Solid Tumor1 trial

Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·MMayo Clinic·Phase 1·NCT00005068

Solid Tumor Malignancies1 trial

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

Unknown status·GGeorgetown University·Phase 1·NCT01522989·37 enrolled

Unresectable Cancer1 trial

Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer

Unknown status·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00004173

Cholangiocarcinoma1 trial

Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00338988·44 enrolled

Sintilimab1 trial

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT07474103·49 enrolled

Locally Advanced1 trial

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Recruiting·UUniversity of Chicago·Phase 4·NCT02366819·36 enrolled

Adjuvant Therapy1 trial

Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1

Withdrawn·ZZhejiang University·Phase 2·NCT02129322

Gastrointestinal Tumors1 trial

Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02319018·14 enrolled

Bevacizumab1 trial

Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc

Terminated·—·Phase 2·NCT00755118·24 enrolled

Ovarian Cancer1 trial

Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer

Unknown status·UUniversity of Leicester·Phase 2·NCT00004206

Pancreatic Adenocarcinoma1 trial

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00075452

First-line Treatment1 trial

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Unknown status·FFujian Cancer Hospital·N/A·NCT03045770·150 enrolled

Gastroesophageal Junction1 trial

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Completed·WWake Forest University Health Sciences·Phase 1·NCT01561014·9 enrolled

Intraperitoneal1 trial

Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00625092·17 enrolled

Gastroesophageal Junction Carcinoma1 trial

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Completed· BeiGene logo

BeiGene·Phase 3·NCT03777657·997 enrolled

Safety and Efficacy1 trial

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02715531·243 enrolled

Locally Advanced Colon Cancer1 trial

Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer

Recruiting·RRuijin Hospital·Phase 2·NCT06368141·56 enrolled

Rectal Cancer Patients1 trial

Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients

Completed·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT01554059·25 enrolled

Lenalidomide1 trial

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01183663·180 enrolled

Small Bowel Cancer1 trial

Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00019773

Lymphoma1 trial

Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006473·72 enrolled

Recurrent or Metastatic1 trial

Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

Terminated·UUniversity of California, Irvine·Phase 2·NCT00256269·4 enrolled

Esophageal Squamous Cell Carcinoma1 trial

PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Unknown status·MMian XI·Phase 2·NCT03791905·216 enrolled

Bladder Cancer1 trial

Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

Completed·SStanford University·Phase 2·NCT00186277·10 enrolled

Efficacy and Safety1 trial

Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University··NCT06504901·30 enrolled

Liver Metastases1 trial

Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases

Unknown status·AArbeitsgruppe Lebermetastasen und Tumoren·Phase 3·NCT00156975·384 enrolled

Unknown Primary Cancer1 trial

Gemox as First and Second Line Therapy in Unknown Primary Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00353145·29 enrolled

Gastroesophageal Junction Cancer1 trial

Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer

Terminated·UUniversity of Nebraska·Phase 2·NCT01307956·11 enrolled

Neoadjuvant Treatment1 trial

mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03043729·119 enrolled

Metastatic Colon Cancer1 trial

Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer

Terminated·UUniversity of Miami·Phase 2·NCT00276861·10 enrolled

Other Solid Tumors1 trial

Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors

Completed·WWashington University School of Medicine·Phase 1·NCT00660426·30 enrolled

Active, not recruiting·—·Phase 2·NCT07480850·40 enrolled

Metastatic1 trial

Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00755534·68 enrolled

Prostate Cancer1 trial

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

Completed·UUniversity of Southern California·Phase 2·NCT01338792·47 enrolled

Biliary Cancer1 trial

Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers

Completed·NNational Health Research Institutes, Taiwan·Phase 1·NCT03162510·18 enrolled

Stage IV Colon Cancer1 trial

Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery

Completed·NNSABP Foundation Inc·Phase 2·NCT00321828·90 enrolled

Advanced Solid Tumors1 trial

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT01362374·122 enrolled

Capecitabine1 trial

Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1

Completed·FFudan University·Phase 3·NCT02605265·356 enrolled

Toripalimab1 trial

HAIC Combined With Toripalimab and Donafenib for Advanced BTC

Unknown status·LLu Wang, MD, PhD·Phase 2·NCT05350943·70 enrolled

Salivary Gland Cancer1 trial

Title XELOX FOR SALIVARY GLAND CANCERS

Terminated·—·Phase 2·NCT00101075·9 enrolled

Malignancy1 trial

Study of GemOx and Vandetanib in Advanced Solid Malignancy

Completed·LLeonard Appleman·Phase 1·NCT00660725·22 enrolled

Immunotherapy1 trial

Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG

Unknown status·UUniversity Hospital, Essen·Phase 2·NCT04062656·21 enrolled

Intestinal Cancer1 trial

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Completed·AAnne Noonan·Phase 1·NCT04164069·9 enrolled

Recurrent Rectal Cancer1 trial

Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer

Not yet recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT06751394·44 enrolled

Fallopian Tube Cancer1 trial

Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Completed·NNYU Langone Health·Phase 1·NCT00006391

Metastasis1 trial

Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis

Withdrawn·WWestern Regional Medical Center·Phase 2·NCT02345746

Advanced or Metastatic Solid Tumors1 trial

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting·SSuzhou Transcenta Therapeutics Co., Ltd.·Phase 1/2·NCT04495296·320 enrolled

Mesothelioma1 trial

Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma

Completed·—·Phase 2·NCT00859469·29 enrolled

Rectal Carcinoma1 trial

Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma

Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 2·NCT00297141·60 enrolled

Growth1 trial

A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer

Completed· Roche logo

Roche·Phase 2·NCT01748773·34 enrolled

DLBCL1 trial

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Recruiting·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT07451652·10 enrolled

Gastric1 trial

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

Completed·UUS Oncology Research·Phase 2·NCT00517829·150 enrolled

Unspecified1 trial

Phase I FOLFOX Combination

Completed· Sanofi logo

Sanofi·Phase 1·NCT00499850·18 enrolled

Regulatory

FDA Approval Timeline[5]

Aug 9, 2002

ELOXATIN

NDA NDA021492

Jan 31, 2005

ELOXATIN

NDA NDA021759

Aug 7, 2009

OXALIPLATIN

NDA NDA022160

Sources

References

[1]
ClinicalTrials.gov — 1240 trial records for Oxaliplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Eloxatin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Oxaliplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Oxaliplatin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022160). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Teva

Eloxatin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Colorectal Cancer27 trials

Metastatic Colorectal Cancer26 trials

Pancreatic Cancer15 trials

Gastric Cancer12 trials

Esophageal Cancer6 trials

Locally-advanced Rectal Cancer6 trials

Liver Cancer5 trials

Radiation Therapy5 trials

Non-Small Cell Lung Cancer4 trials

Patients With Advanced Solid Tumors3 trials

Rectal Cancer3 trials

Stage III Colon Cancer3 trials

Gemcitabine2 trials

Oxaliplatin2 trials

Biliary Tract Cancer2 trials

Adjuvant Treatment2 trials

Adenocarcinoma2 trials

Hepatocellular Carcinoma2 trials

Metastatic Head and Neck Cancer2 trials

Rectal Adenocarcinoma2 trials

Esophageal Adenocarcinoma2 trials

Nasopharyngeal Carcinoma1 trial

Metastatic Cancer1 trial

Microsatellite Instability1 trial

PD-1 Inhibitor1 trial

Stomach Cancer1 trial

Transplantation1 trial

Primitive Neuroectodermal Tumor1 trial

Chemotherapy1 trial

Myelodysplastic Syndromes1 trial

Advanced Cancer1 trial

Head and Neck Cancer1 trial

Advanced Biliary Tract Carcinoma1 trial

Unresectable Solid Tumor1 trial

Solid Tumor Malignancies1 trial

Unresectable Cancer1 trial

Cholangiocarcinoma1 trial

Sintilimab1 trial

Locally Advanced1 trial

Adjuvant Therapy1 trial

Gastrointestinal Tumors1 trial

Bevacizumab1 trial

Ovarian Cancer1 trial

Pancreatic Adenocarcinoma1 trial

First-line Treatment1 trial

Gastroesophageal Junction1 trial

Intraperitoneal1 trial

Gastroesophageal Junction Carcinoma1 trial

Safety and Efficacy1 trial

Locally Advanced Colon Cancer1 trial

Rectal Cancer Patients1 trial

Lenalidomide1 trial

Small Bowel Cancer1 trial

Lymphoma1 trial

Recurrent or Metastatic1 trial

Esophageal Squamous Cell Carcinoma1 trial

Bladder Cancer1 trial

Efficacy and Safety1 trial

Liver Metastases1 trial

Unknown Primary Cancer1 trial

Gastroesophageal Junction Cancer1 trial

Neoadjuvant Treatment1 trial

Metastatic Colon Cancer1 trial

Other Solid Tumors1 trial

Neoadjuvant Immunotherapy1 trial

Gastric Adenocarcinoma1 trial

Diffuse Large B-Cell Lymphoma1 trial

Metastatic1 trial

Prostate Cancer1 trial

Biliary Cancer1 trial

Stage IV Colon Cancer1 trial

Advanced Solid Tumors1 trial